Study of Norplant® implants in Shanghai: Three‐year experience

Du, Ming; Zheng, H.M.; Chen, H.C.; Chow, L. P.

doi:10.1016/0020-7292(90)90521-l

Cited by 21 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reports in the literature concerning platelet count showed lack of consensus (Shaaban et al, 1984;Sivin, 1988;Du et al, 1990;Singh et al, 1993), even though the platelet count at 12 months decreased signi cantly compared to preinsertion concentration (Aisien et al, 2000). The values at 24 and 36 months of studies did not show signi cant change over the 12-month data.…”

Section: Discussionmentioning

confidence: 49%

See 1 more Smart Citation

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception

Aisien

Sagay

Imade

et al. 2002

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

This ongoing prospective longitudinal study involved 23 women who had complete records, of 37 healthy non-breastfeeding informed volunteers recruited from our family planning clinic since August 1997 to the Norplant training programme. Packed cell volume (PCV), white blood cell (WBC) concentration (total and differential and platelet concentration were analysed at pretreatment and at 12, 24 and 36 months' followup. Statistical analysis was with paired t-tests. The level of significance was set at 5%. Each acceptor received a menstrual calendar to document all events of bleeding. The mean PCV was 40.5 +/- 2.4% at pretreatment. This rose to a statistically significant (P < 0.001) mean value of 44.9 +/- 4.4% at 36 months. The mean WBC concentration at pretreatment was 5552 +/- 1423 per mm3 which declined statistically (P < 0.001) to a mean value of 4400 +/- 1281 per mm3 at 12 months without any further significant changes at 24 months (P > 0.6; 4143 +/- 1301 per mm3 and at 36 months (P > 0.9; 4070 +/- 875 per mm3). At 24 months of study the mean concentration of neutrophils, lymphocytes, monocytes eosinophils and basophils did not change significantly from their respective mean concentrations at 12 months. These insignificant changes were also manifested at 36 months of study in the lymphocytes (P > 0.2), eosinophils (P > 0.5) and basophils (P > 0.2), even though there was a significant decrease in the neutrophils (P < 0.05) with a corresponding significant increase (P < 0.001) in the monocyte concentration. However, there was still a significant decrease (P < 0.001) in the WBC at 36 months of study compared with the mean preinsertion value, which was manifested mainly in the neutrophil concentration (1403 +/- 517 per mm3 (P < 0.001). The mean value of platelet count (136260 +/- 27664 per mm3) at 24 months showed no significant change compared with the 12 months value (126174 +/- 37977 per mm3). The value at 36 months (125391 +/- 18858 per mm3), however, still showed a significant decline over the pretreatment mean concentration (208043 +/- 27250 per mm3). None of the acceptors had thrombocytopenia at 24 and 36 months. At 2 years and 3 years of studies 60.9% and 47.8% of Norplant users reported irregular bleeding patterns, mainly of reduced episodes. The continuation rate at 36 months was 100%. Women using the Norplant implant are at an advantage, because in spite of the variable aberrations in their menstrual pattern, the packed cell volume increased. The changes ob-served in the white cell and the platelet concentrations did not lead to adverse effects.

show abstract

Section: Discussionmentioning

confidence: 49%

“…Any Norplant effect on platelet concentration has shown lack of consensus, varying from no change, to decrease concentration or an increase in value (Shaaban et al, 1984;Sivin, 1988;Du et al, 1990;Singh et al, 1993). Norplant has been in use in our centre for about 15 years and is gaining popularity.…”

Section: Introductionmentioning

confidence: 97%

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception

Aisien

Sagay

Imade

et al. 2002

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…The incidence of abnormal P/V bleeding following norplant insertion was 9.4% (54 out of 574) which is lower compared to other similar studies conducted elsewhere (20-30%). 2,3 Participants in this trial came to the clinic because of complaints of prolonged or irregular bleeding. In the present study a substantial proportion (84%) of the clients responded to treatment with DMPA and most (66.7%) of the cases required only one dose and the rest required 2 doses.…”

Section: Discussionmentioning

confidence: 99%

“…1 All the reports on its introduction and use in different countries and settings have shown that 20-30% of norplant implant users experience irregular, unpredictable uterine bleeding. [2][3][4][5][6] Irregular bleeding is the principal side effect associated with use of norplant. Pathophysiology of irregular uterine bleeding is still unknown and its management to date has been empirical.…”

Section: Introductionmentioning

confidence: 99%

Role of Injection Depo Medoroxy Progesterone Acetate in the Management of Abnormal Uterine Bleeding in Norplant User

Begum

Nahar

Sultana³

et al. 2019

Ibrahim card. med. j.

View full text Add to dashboard Cite

Background & objective: This prospective study was undertaken to determine the role of Depomedroxy progesterone acetate (DMPA) in the management of abnormal uterine bleeding associated with norplant use. Methods: The study was carried out in the Department of Family Planning Model Clinic of Sir Salimullah Medical College and Mitford Hospital, Dhaka between June, 2003 to December, 2005. A total 54 clients were consecutively selected, based on predefined enrolment criteria. Results: Over two-thirds (70.6%) of the patients were multipara (2-3 live births), 22% primipara and the rest 7.4% grand-multipara (4 or more live births). Among 54 cases, 45(84%) responded to treatment. Of the 9 (16%) cases who failed to respond to DMPA treatment, 4 cases were given 2nd dose of DMPA. Three cases dropped out after failing the 1st dose and 2 cases refused to receive 2nd dose and their norplant was removed on request. Abnormal per vaginal (P/V) bleeding began from the 1st month of insertion of Norplant with 15 (27.7%) cases in the 1st month, 7(12%) cases between 2nd to 5th months, 16(28%) cases between 6-12 months, 11(20%) between 13-24 months and 5 (9.3%) cases between 25-36 months. Conclusion: The study showed that DMPA is a simple and effective modality of treatment for women with abnormal or irregular uterine bleeding associated with norplant implant use. With increased compliance from clients’ perspective, it could be a good option for treatment of women with abnormal or irregular uterine bleeding caused by norplant implant. Ibrahim Card Med J 2017; 7 (1&2): 80-83

show abstract

Hormonal contraceptives for contraception in overweight or obese women

Lopez

Grimes²,

Chen

et al. 2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Study of Norplant® implants in Shanghai: Three‐year experience

Cited by 21 publications

References 6 publications

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception

Role of Injection Depo Medoroxy Progesterone Acetate in the Management of Abnormal Uterine Bleeding in Norplant User

Hormonal contraceptives for contraception in overweight or obese women

Contact Info

Product

Resources

About

Study of Norplant® implants in Shanghai: Three‐year experience

Cited by 21 publications

References 6 publications

Evaluation of menstrual and haematological parameters, after 36 months of NorplantRcontraception

Evaluation of menstrual and haematological parameters, after 36 months of NorplantRcontraception

Role of Injection Depo Medoroxy Progesterone Acetate in the Management of Abnormal Uterine Bleeding in Norplant User

Hormonal contraceptives for contraception in overweight or obese women

Contact Info

Product

Resources

About

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception

Evaluation of menstrual and haematological parameters, after 36 months of Norplant^Rcontraception